DR REDDYS LABORATORIES LTD
No enriched coverage for $RDY in the last 7 days.
No SEC Form 4 filings for $RDY in the last 30 days.
Canada has approved its first generic versions of the diabetes drug Ozempic, developed by Dr Reddy's Laboratories. This approval, following the expiry of Novo Nordisk's patent in Canada, is expected to significantly reduce treatment costs and intensify competition in the global GLP-1 therapy market.
DR REDDYS LABORATORIES LTD director Arun Madhavan Kumar has filed an initial Form 3, establishing his status as a reporting insider. This filing, dated March 27, 2026, is a mandatory statement of beneficial ownership and does not indicate any transactions or holdings. It serves to set a baseline for future ownership disclosures by Mr. Kumar.
JPMorgan Chase & Co. increased its stake in Dr. Reddy's Laboratories Ltd (NYSE:RDY) by 2.0% in the third quarter, acquiring an additional 116,924 shares and now owning 0.72% of the company worth $84.27 million. Other institutional investors also adjusted their holdings, while analysts currently hold an average "Hold" rating for the stock with a consensus price target of $16.90. Dr. Reddy's Laboratories reported earnings per share of $0.16, meeting consensus estimates, and revenue of $969.81 million for the last quarter.
